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1 Introduction
Neutrophil granulocytes, the major group of leukocytes in healthy human blood,
are terminally differentiated cells of myeloid lineage. Histologically, they can be
identified based on their "neutral" - as opposed to eosinophilic or basophilic - cy-
toplasm, their segmented nucleus, as well as cytoplasmatic granules. They play a
key role in innate immunity, and perform modulatory functions in adaptive immunity.
Due to this central role in immunity, neutrophils express a wide array of receptors
such as G-protein coupled receptors (GPCR), Toll-like receptors (TLR), Leukotriene
B4 receptor, immunoglobulin Fc receptors and potent enzymes such as neutrophil
elastase (NE), myeloperoxidase (MPO) and matrix metalloprotease 9 (MMP9). Im-
portant functions include shaping immune responses, mediating tissue injury and
repair, and killing microbes. Several main mechanisms for killing pathogens have
been established, including phagocytosis, degranulation and neutrophil extracellu-
lar traps (NETs)1,2. In some (auto-)immune diseases and conditions however, these
powerful tools are involved in the destruction of healthy tissues3,4. Additionally, their
complex role in cancer pathophysiology is beginning to be elucidated5. However,
targeting neutrophils in disease has to be balanced with their important physiologi-
cal roles6.
In a classic acute inflammation setting, tissue injury directly and indirectly re-
leases a plethora of cytokines, including tumor necrosis factor alpha (TNF-α), che-
mokines and interleukins through tissue-resident macrophages and other resident
cells. Circulating neutrophils and endothelial cells are then activated by elevated
concentrations of these chemokines and neutrophils are recruited into tissue where
they exert their effector functions, e.g. phagocytosis of the bacteria, attraction of
other immune cells or induction of tissue repair. The extravasation or recruitment is
a hallmark feature of neutrophils and due to its tight regulation represents a poten-
tial target for therapeutic inhibition7.
1.1 Recruitment Cascade
The recruitment of neutrophils from the blood consists of tethering, rolling, adhesion
and transmigration and is visualized in Figure 1. Circulating neutrophils are teth-
ered to the endothelium and begin to roll. This is mediated through selectins on the
endothelium (such as E-selectin and P-selectin) and selectin ligands on the neu-
trophil (such as P-selectin glycoprotein ligand 1/PSGL1, E-selectin ligand 1/ESL1
or cluster of differentiation 44/CD44). The next step is adhesion, where the neu-
trophil sticks to the endothelium. This process is mediated through the interaction
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of integrin ligands on the endothelium (intercellular adhesion molecule 1/ICAM-1
and vascular cell adhesion molecule 1/VCAM-1) and β2 and β1 integrins on the
neutrophil, respectively. The adhesion is strengthened by conformational change
of integrins on the neutrophil and the neutrophil begins crawling in order to search
for a suitable spot to transmigrate through the endothelium, either between two
endothelial cells, i.e. paracellular route, or through one endothelial cell, i.e. tran-
scellular route. Important molecules required here are neutrophil elastase (NE),
very late activation leukocyte antigen 3/VLA-3 and very late activation leukocyte
antigen 6/VLA-68.
Figure 1: Neutrophil recruitment cascade and involved molecules. Here, the
phases of neutrophil recruitment from vessel to tissue including the involved
receptors and ligands are visualized. The chemokine receptor inhibitors Ladarixin
(LDX), DF2755A (DF) and Reparixin (RPX) are marked in red in the picture. For a
detailed explanation, please consult text above.
1.2 CXCR1/2 and Their Chemokines in Neutrophil Recruitment
C-X-C chemokine receptors 1 and 2 (CXCR1 and CXCR2) are G-protein coupled
receptors. They are expressed on various immune and non-immune cells including
neutrophils, macrophages and endothelial cells. The ligands of CXCR1/2 are C-X-
C motif chemokines with an additional glutamic acid-leucine-arginine (ELR) motif.
High affinity ligands in humans for CXCR1 are CXCL6 and CXCL8, and for CXCR2
CXCL1-3 and 5-89. In mice and rats, the presence of CXCL8 has not been de-
scribed so far, so its functional equivalent CXCL1 (also called keratinocyte-derived
chemokine/KC) is used instead10. In the following section, we discuss the role of
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these receptors in neutrophils, and particularily their effects on neutrophil recruit-
ment.
As is typical of GPCRs, upon ligand binding, the α subunit is activated while the
βγ subunits dissociate from the complex. This activation of the βγ subunit alone is
sufficient for triggering chemotaxis amongst other critical neutrophil functions11.
One well-studied prerequisite for the induction of adhesion through CXCR1/2 in
neutrophils is the activation of integrins12. Integrins are heterodimeric receptors
expressed in many immune cells including neutrophils. One class of integrins ex-
pressed in neutrophils are β2 integrins, which includes for example leukocyte func-
tionary antigen 1 (LFA-1; Integrin αLβ2) and macrophage-1 antigen (Mac-1; Inte-
grin αMβ2). It has been established that binding of LFA-1 to intercellular adhesion
molecule 1 (ICAM-1) is required for neutrophil arrest and adhesion13.
β2 integrins exist in three different conformations: low, intermediate and high affin-
ity. Upon activation, the integrin switches from low to intermediate affinity state and
the bond between integrin and ligand is strengthened. This change happens as
the neutrophil rolls, so that it rolls slower until it finally arrests13. β2 integrins can
be activated through the activation of chemokine receptors or through the interac-
tion of E-selectin and PSGL-1 during the rolling stage of neutrophil recruitment in
a process called inside-out signaling14,15. Inside-out signaling for integrin activation
requires at least Src and Syk tyrosine kinases16,17. β2 integrins also serve as signal-
ing receptors (so-called "outside-in" signaling) which primes the cell for subsequent
adhesional strengthening and intraluminal crawling. This phase follows arrest and
is characterized by neutrophils crawling along the endothelium in order to find a
suitable spot to cross it. Here, key molecular players include the β2 integrin Mac-1
and the integrin ligand ICAM-118.
In intraluminal crawling, neutrophils are guided especially by chemokine depen-
dent mechanisms, before they finally cross the endothelium in a process called
transmigration. In transmigration, CXCL2 is presented by endothelial cells to neu-
trophils in order to guide them through the vascular wall and into the tissue19. Once
in the tissue, the cells continue their migration towards the source of injury.
In fact, one of the first described roles of CXCR1/2 in neutrophils was chemotax-
is20,21. This means neutrophils can sense a gradient of chemokines and actively
migrate towards a higher concentration. Chemokine receptor inhibitors are usually
selected for their ability to inhibit this chemotaxis behavior22,23. For CXCL8, this
chemotaxis is mostly mediated through CXCR124. Required proteins and factors
for chemotaxis include Ca2+, PI3K, Janus kinase 3 (JAK3), and tyrosine kinases
Cbl and Akt25–28.
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Another effect mediated through CXCR1 is the production of reactive oxygen
species (ROS), which serves as an attractant to other immune cells, as well as
a defense against pathogens2,29.
The activation of CXCR1/2 also leads to changes in Ca2+ levels. Upon G protein
activation and βγ dissociation, phospholipase C is activated which cleaves phos-
phatidylinositol 4,5-bisphosphate (PIP2) to inositoltriphosphate (IP3). IP3 in turn ac-
tivates IP3-sensitive receptors on the endoplasmatic reticulum (ER) which release
stored Ca2+ into the cytoplasm. Through increases in cytoplasmic Ca2+ levels cal-
cium channels on the plasma membrane open and allow extracellular Ca2+ to flow
in. This is also called store-operated calcium entry (SOCE)30. Calcium signaling
in neutrophils has been demonstrated to be essential for β2 integrin activation, mi-
gration, as well as phagocytosis, ROS production and degranulation. Important
intermediate players include Orai1, Stromal interaction molecule 1 and 2 (STIM1,
STIM2), and other non-specific cation channels such as transient receptor potential
(TRP) and P2X channels31.
After ligand binding, the receptors CXCR1 and 2 are endocytosed (internalized),
cleared of their ligand and can be "recycled" back to the membrane. The impor-
tance of this process, which is dependent on G protein coupled receptor kinase
(GRK), β-arrestin and AP-2 adapter protein32,33, for neutrophil recruitment as a
whole is not yet well understood. However it seems to be independent of G pro-
tein signaling, occur only at higher chemokine concentrations - 10-fold higher than
required for inducing a Ca2+ response -, and thus not required for physiological neu-
trophil chemotaxis34. For CXCR2 but not for CXCR1, different ligands have different
profiles of cAMP generation, β-arrestin recruitment, and receptor internalization35.
The chemokines CXCL8 and CXCL1
The chemokine CXCL8, more commonly known as interleukin 8 (IL-8), is a variable-
length protein that can be secreted by many cells, including monocytes, macropha-
ges, fibroblasts, hepatocytes, epithelial and endothelial cells20. It is synthesized as
a 99 amino acid long precursor and then cleaved or truncated depending on cell
type and stimulus36. Many of the aforementioned cells secrete CXCL8 in response
to stimulation with IL-1β or TNF-α. CXCL8 is the prototypical chemokine of CXCR1
and 2, in fact the previous names of these receptors (IL-8 receptor 1 and 2) reflect
exactly this relationship29.
CXCL8’s main physiological role is as a chemoattractant for neutrophils in order
to get to the site of inflammation through activation of CXCR1/2 and Duffy antigen
receptor24,37. Intradermal application of CXCL8 leads to local inflammation, edema
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and neutrophil accumulation at the site of injection. Intravascular injection of CXCL8
leads to severe granulocytopenia, followed by granulocytosis38. CXCL8 and other
chemokines are mostly presented to neutrophils on endothelial cells bound to hep-
aran sulfates2.
A CXCL8 homologue has not yet been discovered in mice. Therefore, for mod-
eling of the CXCR1/2-CXCL8 pathway in mice other ligands of CXCR2 such as
CXCL1/KC or CXCL2 (also called macrophage inflammatory peptide 2 or MIP-
2) are used39,40. However, in rats and mice it has been demonstrated that in-
travascular application of recombinant human CXCL8 also leads to arrest of rolling
neutrophils41,42.
In vitro and in vivo, local application of CXCL1 and to a lesser extent CXCL8 leads
to an increase in adhesion of neutrophils to the vessel walls and accumulation of
neutrophils in tissue42. Gαi2 is required for this arrest, which is why this effect can
be suppressed using Pertussis toxin43. As mentioned, a molecular correlate of this
observation is the activation of β2 integrins.
In summary, CXC chemokine receptors 1 and 2 are G-protein coupled receptors
which bind various CXC chemokines, where the promiment examples are CXCL8 in
humans and CXCL1 (KC) in mice. Important functions of these receptors on a cellu-
lar level include chemotaxis, adhesion, transmigration and on a molecular/signaling
level Ca2+ influx, ROS production and β2 integrins activation. In response to high
chemokine concentrations, the receptors are endocytosed, cleared of the ligand
and recycled back on to the plasma membrane.
1.3 Pathophysiology of the CXCL8-CXCR1/2 axis
Lung diseases
In classic acute bacterial or fungal infections, e.g. with Candida albicans or Es-
cherichia coli, production of CXCL8 and subsequent activation of CXCR1/2 leads
to leukocyte recruitment and activation, which is a prerequisite for killing microbes
at the infection site44. This means inhibition of these receptors would not be ben-
eficial, but hinder healing. One exception is Klebsiella pneumoniae pneumonia,
where the opposite is true: disease is improved upon CXCR1/2 inhibition as ev-
idenced by lower airway neutrophil count and lower lung myeloperoxidase levels,
among others45.
In acute lung injury (ALI) and its late stage called acute respiratory distress
syndrome (ARDS), loss of endothelial and epithelial barriers leads to lung edema
and impaired gas exchange, while influx of immune cells especially neutrophils and
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release of cytokines further damage lung tissue. Even with treatment, ALI may
progress to ARDS and/or irreversible lung fibrosis. With a mortality of 29-42% for
ARDS, it is evident that there are is an unmet need in the treatment of this con-
dition. Currently ALI/ARDS patients receive supportive treatment, mainly in the
form of mechanical ventilation46. The implication of neutrophils and CXCL8 in the
pathophysiology of this disease complex have been clearly described47. Some
research using inhibitors has been done in experimental animal models of this
disease. In mice, CXCR2 blocking antibodies or CXCR2 genetic loss attenuated
sterile ALI severity48,49. Similarily, inflammatory activity was diminished in murine
cigarette smoke and organic barn dust induced ALI after small molecule and pep-
tide CXCR1/2 inhibitor treatment50,51.
Another lung disease with neutrophil and CXCR1/2 involvement is chronic ob-
structive pulmonary disease (COPD). It is a progressive lung disease charac-
terized by an overshooting immune reaction leading to mucus hypersecretion, ob-
structive bronchiolitis and emphysema. Current treatment (sympathomimetics, an-
ticholinergics, inhaled corticosteroids) is only symptomatic and unable to stop pro-
gression of the disease52. CXCL8, its mRNA, and neutrophilic enzymes such
as NE are present in the sputum of COPD patients, where higher levels corre-
late with higher disease severity53,54. In vitro inhibition of CXCR2 on neutrophils
from COPD patients’ sputum reduced their chemotaxis to sputum supernatant55.
Multiple CXCR2 inhibitors were tested in clinical trials for COPD, including small
molecule inhibitors and monoclonal anti-CXCL8 antibodies. All tested compounds
led to improvements in markers such as dyspnea, sputum or blood neutrophils,
but not in overall disease severity56,57. Danirixin slightly improved the occurrence
of exacerbations and COPD scores, and is currently undergoing a dose ranging
study58–61. Despite promising preclinical evidence however, inhibiting cytokines and
specifically CXCL8 in COPD has so far only shown very limited clinical therapeutic
effect62.
Asthma is also a chronic progressive airway disease, characterized by hyper-
secretion, bronchospasm, edema and long-term airway remodeling. Attacks can be
caused by a wide range of factors, the most common being allergen exposure and
viral/bacterial infections. Airway obstruction in COPD and asthma can be quanti-
fied using the forced exhaled air volume in 1 second (FEV1). Treatment is similar to
COPD and intervenes at two pathophysiological levels: bronchodilators (especially
β sympathomimetics) for acute attacks and anti-inflammatory drugs (especially in-
haled corticosteroids) for middle to long term prevention of attacks. Despite the fact
some researchers argue for a role of neutrophils in the early phase of an attack and
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neutrophil recruitment is seen in the late phase, their exact role in asthma remains
elusive63,64. Similar to COPD, an increase of CXCL8 can be seen in the sputum be-
fore an asthma attack44. Clear evidence of the role of the CXCR1/2-CXCL8 axis in
asthma so far is limited to hypersecretion and angiogenesis64,65. Clinical trials with
small molecule inhibitors have been undertaken66,67. One inhibitor reduced neu-
trophil recruitment to the lung/sputum and lowered systemic absolute neutrophil
count (ANC), however both compounds showed only little clinical benefit in terms
of ameliorating FEV1 or preventing attacks/exacerbations66,67.
Autoimmune diseases
The role of neutrophils and the CXCL8-CXCR1/2 axis including its inhibition are
beginning to be unraveled for a variety of autoimmune diseases6.
Type 1 diabetes (T1D) is an autoimmune disease, where the insulin producing
beta islets of the pancreas are progressively destroyed, leading to an unchecked
build-up of blood glucose and all its consequences. Pathophysiologically, immune
cells including neutrophils and T cells attack and destroy these cells. Mounting ev-
idence shows the CXCL8-CXCR1/2 axis plays an important role in the recruitment
of neutrophils to the pancreatic tissue68. Traditionally, T1D is treated with lifelong
parenteral insulin substitution. However, new immunomodulatory drugs, including
CXCR1/2 inhibitors, are starting to emerge: treatment of mice with a CXCR2 in-
hibitor in an experimental T1D model attenuated neutrophil recruitment to the pan-
creas almost completely69. Reparixin was tested in mice and humans regarding
the outcome of islet cell transplantions and was found to consistently improve it as
evidenced by elevated C-peptide levels and lower insulin requirement70.
Psoriasis is a chronic autoimmune disorder which manifests itself primarily on
the skin, but may affect other organs such as joints. The skin inflammation is char-
acterized by erythematosquamous plaques at typical localizations. Pathophysio-
logically, it is classified as a complex genetic deregulation of the immune system
mediated by T cells. Well researched players include Th17 cells, and the inter-
leukins IL-17 and IL-23. Currently, psoriasis is treated with topicals, photother-
apy, and systemic immunomodulants like retinoids, methotrexate, cyclosporine A,
and antibodies71,72. Even though CXCL8 and CXCR1/2 are not main areas of
research72, there is evidence they are present in psoriatic skin lesions and con-
tribute to its pathogenesis73,74. CXCR2 seems to be over-expressed in these le-
sions, while CXCR1 does not seem to be detectable75. CXCL8 staining revealed
some parts of skin lesions, as well as accumulating neutrophils to be positive76.
However, the exact role of neutrophils and the CXCL8-CXCR1/2 axis, and its ther-
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apeutic potential in psoriasis remains to be elucidated.
Rheumatoid arthritis (RA) is a chronic autoimmune disease which leads to
painful deformation and destruction of joints. Key pathophysiological features in-
clude the so-called rheumatoid factor (autoantibodies) and an overproduction of
TNFα, leading to persistent sterile inflammation of the synovia. Current treat-
ment recommendations include non-steroidal anti-inflammatory drugs (NSAIDs)
like ibuprofen, disease-modifying anti-rheumatic drugs (DMARDs) like methotrex-
ate, and antibodies like anti-TNFα. Similar to psoriasis, its prevalence of 0.5-1%
precludes a big interest in novel therapies77. The involvement of neutrophils and
CXCL8 is well documented in literature: CXCL8 can be detected at high levels in
serum, as well as synovial fluid of RA patients78. Mononuclear phagocytes from
RA patients spontaneously produce CXCL879. The synovial membrane and other
structures in RA can be positively stained for CXCL880. Neutrophils can be detected
in synovial fluid very early, and it is thought they are a key player in orchestrating the
immune response in RA through the production of various cytokines and ROS81. In
arthritis models in mice82,83 and rats84,85 it was demonstrated that small molecule
inhibition of CXCR1/2 leads to reduced disease activity markers, including PMN
recruitment and hyperalgesia.
Ulcerative colitis (UC) is a chronic autoimmune disease of the intestinal mu-
cosa, mainly the rectum and colon. The inflammation of the intestine generates
symptoms such as bloody diarrhea, malabsorption and pain, usually in a biphasic
manner (flare-up and remission). Discovered pathophysiological features include
the relevance of innate lymphoid cells, T helper cells, IL-13 and IL-4 as drivers of
the disease. Also, dysbiosis and TLR2 and 4 upregulation is seen, though it is
unclear whether these are causes or consequences. Current treatment options in-
clude 5-aminosalicylates, corticosteroids, 5-mercaptopurine, anti-TNF antibodies,
and – as ultima ratio – proctocolectomy86. Neutrophils, CXCL8 and its receptors,
also seem to be involved in the pathogenesis of UC: depletion of PMN and inhibition
of leukocyte adhesion in a rat model attenuated experimental UC, and in humans,
CXCL8 and CXCR1/2 expression is increased in UC and can be correlated with
different disease phases and severity87. Neutrophil infiltration is also one of the
major criteria in two histological grading systems for UC88. In a CXCR2 knockout
study in mice, Buanne and colleagues found that Cxcr2−/− mice were protected to
a certain degree from experimental UC, as evidenced by reduced PMN infiltration,
lower disease scores, improved histopathology, and lower MPO activity89.
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Malignancies
The role of the CXCL8-CXCR1/2 axis in malignancies has been well established.
Tumors interact in many ways with the immune system, and induce angiogenesis
to sustain growth90. Neutrophils and other immune cells have ambivalent roles in
tumors5.
While the overall role of neutrophils in malignancies is complex, tumor-associated
neutrophils (TAN) can be broadly classified based on their anti-tumor (N1) or pro-
tumor (N2) phenotypes. Though this phenotype often changes in the course of
the disease, many reports indicate an overall pro-tumor (N2) role for neutrophils5,6.
Specifically, it is thought that neutrophils are recruited to the tumor tissue and by
releasing their enzymes and destroying the extracellular matrix (ECM), they pave
the way for other cells to grow in this space91. CXCR2 knockout studies in mice
provide evidence that at least for prostate92, pancreatic93, breast94, colorectal95 and
lung cancer96, absence of the receptor interferes with disease progression in terms
of reduced tumor volume, and less angiogenesis. Studies using small molecule
inhibitors instead of knockout animals are starting to emerge, for example inhibition
of malignant melanoma cell growth97,98, colon cancer cell metastasis formation99
and prostate cancer cell growth and vascularization100. In Ras-driven cancers, in-
hibition of CXCL8 using an antibody attenuates their growth101. Overall, inhibition
of the CXCL8-CXCR1/2 axis in malignancies seems to have a beneficial effect in
clinical animal disease models.
Other diseases
Alcoholic steatohepatitis (ASH) is a sterile inflammation of the liver resulting from
excessive long-term alcohol consumption. ASH usually manifests itself through liver
failure, and if left untreated leads to cirrhosis and eventually end-stage liver disease
and death. Pathophysiologically, chronic alcohol consumption severely disturbs the
liver fatty acid, ROS and enzyme metabolism. Treatment is usually symptomatic,
and abstinence does not guarantee remission of the disease. Immunomodulators
like corticosteroids and anti-TNFα drugs have been tested with mixed results102.
Chemokines which seem to be involved in the recruitment of neutrophils to liver
tissue include CXCL2 and to a lesser extent CXCL1103. To date, evidence of the
direct involvement of CXCL8 in ASH is lacking, however patients might still profit
from CXCR1/2 inhibition, since these receptors also bind CXCL1 and 2. In fact, in
a murine ASH model CXCR1/2 pepducins were able to stop progression as well as
reverse disease progression to some extent104.
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Sepsis is a clinical condition characterized by acute organ dysfunction and infec-
tion of the blood, with mortality rates around 20-50%. All organs can be affected,
though lung and cardiovascular system play a major role early in the course, while
at later time points brain and kidney injury are predominant. Septic shock is a pos-
sible and severe complication. Pathophysiologically, early pro-inflammatory path-
ways lead to collateral damage to the organs, while late anti-inflammatory signals
preclude an increased susceptibility to secondary infections. Treatment currently
consists of antibiotics, and supportive intensive care ("hit early, hit hard")105. Neu-
trophils, being key cells of the innate immune system, are involved in the patho-
genesis of sepsis and related clinical models of vascular inflammation106. It is
well-described that septic neutrophils exhibit significant migration defects. While
CXCR2 expression on neutrophils is significantly decreased in comparison with
healthy control107, CXCL8 in sepsis has been described as a biomarker of disease
severity and predictor of outcome108,109. Blocking CXCR1/2 has lead to very mixed
results in experimental sepsis models: while CXCR1/2 inhibition110 and CXCR2
knockout111 lead to increased survival in septic peritonitis, CXCR1 activation is
a protective factor in Candida albicans sepsis112. To this end, the exact role of
CXCR1/2 in sepsis therefore remains unclear and might depend on the dose and
timing of CXCR1/2 activation/inhibition.
Ischemia reperfusion (I/R) injury is a condition which results from reapplying
blood flow to tissues which before were ischemic, where it was observed that tissue
damage is much greater than can be explained by ischemia alone. This type of
condition can affect all organs and tissues, but is predominantly seen in patients
with myocardial infarction, stroke and after hepatic and renal transplants. Depen-
dent on the size and ischemia time of the tissue, remote neutrophil accumulation
can be seen in the lung, which manifests itself clinically as pulmonary edema. On
a molecular level, ROS production by neutrophils leads to direct and indirect tis-
sue damage. Treatment consists of supportive measures such as hypothermia, the
goal being to limit the organism’s oxygen need113. A plethora of novel therapeu-
tics targeting the immune system are currently being investigated114. Involvement
of neutrophils appears to be negligible for at least very severe cerebral ischemia
in rats115, while direct involvement of the CXCL8-CXCR1/2 axis so far has been
demonstrated at least in myocardial infarction116. In vivo inhibition studies show
that CXCR1/2 inhibition limits neutrophil influx to I/R areals22,117–122. A suppression
of tissue damage was observed in several studies in rat liver118,119, rat cerebral22,120
and rat gut121,122 I/R models, while in another experiment using a mouse cerebral
I/R model no effects on tissue damage were noted117. In summary, there are many
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reports demonstrating that CXCR1/2 inhibition in I/R clinical disease models can
limit neutrophil influx, and possibly associated tissue damage.
Alzheimer’s disease (AD) is a chronic degenerative disease of the brain char-
acterized by accelerating dementia. Amyloid β (Aβ) peptide, a variable length pep-
tide cleaved from amyloid precursor protein (APP), accumulates in the extracellular
spaces of the brain. In the intracellular space, the cytoskeleton physiology is dis-
turbed leading to accumulation of tau proteins. Alterations of enzymes, which are
responsible for cleaving APP, can shift the balance to overproduction. The accumu-
lation of these proteins finally leads to microglial activation, loss of synapses and
cell death. The atrophy progresses in such a manner that it generates the dementia
symptoms. Treatment is purely symptomatic, consisting of cholinesterase inhibitors
for cognitive symptoms, and neuroleptics for psychiatric symptoms123. The role of
CXCR2 in AD pathophysiology is starting to emerge. Stimulation with CXCL8 in-
creases Aβ production in vitro. Furthermore, small molecule inhibition or CXCR2
silencing inhibited the production of two amyloid β peptides in vitro124. These find-
ings were later confirmed by the same group in a murine AD model in vivo using
Cxcr2−/− mice125. Small molecule CXCR1/2 inhibition also inhibited Aβ production,
among other markers for AD, in rats126.
In summary, CXCR1/2 and its main chemokine in humans CXCL8 are involved in
many diseases and conditions. While for some diseases like ischemia/reperfusion
injury, cancer AD and RA important therapeutic effects of CXCR1/2 inhibition are
beginning to be unraveled, in others such as asthma, COPD, there seems to be little
clinical benefit of CXCR1/2 inhibition. For acute infections including sepsis there
seem to be conflicting roles of the CXCL8-CXCR1/2 axis. Finally, for diseases like
ASH, PKD, UC, psoriasis, and T1D, there is still little known about the efficacy of
CXCR1/2 inhibition despite promising first hints.
1.4 Inhibitors of CXCR1/2
A variety of inhibitors of CXCR1 and/or 2 from different classes have been de-
scribed to date (see Table 1).
One of the first to be used was the toxin of Bordetella pertussis (Pertussis toxin;
PTx), which was first discovered to inhibit neutrophil activation127, and later CXCL1-
mediated adhesion in mice in vivo42. On a molecular level, it catalyzes the ADP-
ribosylation of the Gα subunits Gαi1−3 and Gαo1−2 which prevents downstream G
protein signaling. It is noteworthy that in clinical models e.g. peritonitis, PTx only
partially blocks neutrophil recruitment42. Because of its inherent wide range of
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(side-)effects on the human body, it is not used in the therapy of diseases. How-
ever, it remains a valuable tool in the research of chemokine-mediated neutrophil
activation, and also was used in this project.
The diaryl urea class of inhibitors includes the compounds SB225002128, SB-
33223584, SB656933129 and GSK1325756 (Danirixin)130,131. In vitro and in vivo
experiments were conducted with these compounds proving their efficacy. Clinical
models included arthritis and ALI models in rats and peritonitis models in mice.
Danirixin was also investigated in humans in phase 1 and phase 2 clinical trials
for COPD, where first results show slight improvement of diseases activity with no
relevant adverse events58–61.
Another class of inhibitors are boronic acid containing molecules which includes
the compounds SX-517143, SX-576142,148 and SX-862144,145. SX-517 and SX-576
showed lowering of neutrophil influx and activation in human in vitro and mouse/rat
in vivo models. SX-862 showed inhibition of myeloid-derived suppressor cell traf-
ficking in vivo in mouse advanced malignant tumor models.
Compounds from Dompè (L’Aquila, Italy) include Ladarixin119, Reparixin (Reper-
taxin)118, DF216285,138 and DF2755A137. These compounds were tested for their
efficacy in in vitro chemotaxis assays, as well as rat liver I/R, arthritis, and mouse
T1D and nociception models. Further clinical trials have been conducted with some
of the compounds (Table 2).
Some inhibitors such as Antileukinate, NAc-PGP, CXCL8 K11R G31P or pep-
ducins are peptide-based. Antileukinate was first described in 1995 and tested in
neutrophil activation, chemotaxis, and recruitment in vitro and in vivo models147,149.
N-Acetyl-Proline-Guanine-Proline (NAc-PGP) is a peptide which was found in the
degraded extracellular matrix following airway inflammation and neutrophil influx150.
Its isomer DD-NAc-PGP was later discovered to be a competitive CXCL8 antagonist
in chemotaxis assays132. CXCL8(3-73) K11R G31P (short G31P) is a CXCL8 ana-
logue with two mutations (at positions 11 and 31, respectively), and was reported
to have a higher affinity on CXCR1 and 2 than native CXCL8, while suppress-
ing neutrophil activation and chemotaxis151,152. It was also effective in attenuating
pulmonary inflammation in an experimental K. pneumoniae pneumonia guinea pig
model45.
Pepducins are lipid-conjugated proteins which target intracellular loops of G pro-
teins. Lipids, such as palmitate, are appended N-terminally to intracellular loops,
e.g. i3 or i1, of G-protein coupled receptors. The lipid allows these molecules to
float in the cell membrane and disrupt the activation of G-proteins via these recep-
tor intracellular loops153. They are named after the receptor they target, then the
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Table 1: Overview of CXCR1/2 inhibitors.
Class Name References




Peptide Pertussis toxin 42
Competition or binding of CXCL8
Mutated peptide CXCL8 K11R G31P 100
Small peptide DD-NAc-PGP isomer 132




























The table is grouped by mechanism of action and chemical class of the inhibitor.
For details, see section 1.4.
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conjugated lipid, and finally the intracellular loop, for example x1/2-pal-i1 is a pep-
ducin targeting CXCR1/2 (x1/2), has palmitate conjugated (pal), and interacts with
the first intracellular loop (i1). Pepducin x1/2-pal-i3 and x1/2-LCA-i1 inhibit neu-
trophils in vitro in calcium signaling assays, as well in vivo in a murine peritonitis
model. The group also reported that the administration of the pepducins protected
the mice from death due to sepsis, even if the administration occured delayed154.
Pepducin x1/2-pal-i1 was synthesized and tested in experimental murine alcoholic
steatohepatitis (mASH)104. It reduced incidence and mortality of mASH, while signs
of reversal of mASH, downregulation of chemokines, and reduction of neutrophil in-
flux in the liver could also be observed.
In summary, different classes of compounds inhibiting CXCR1/2 have been de-
scribed so far. While for some classes such as diaryl urea and compounds from
Dompè, there is already a large body of preclinical data and first clinical trials, other
classes like peptide-based and boronic acid containing inhibitors were so far only
investigated in vitro and a limited amount of preclinical disease models.
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Table 2: Clinical trials with CXCR1/2 inhibitors.














Dompè 2 c NCT02814838
Reparixin Lung transplant I/R Dompè 2 c NCT00224406
Reparixin Post surgical I/R
following coronary
artery bypass graft
Dompè 1 c 122
Reparixin T1D islet cell trans-
plantation










































Ph = Phase. Status: c = completed, t = terminated, r = recruiting. References are
either published results or ID from ClinicalTrials.gov of National Library of Medicine
at the US National Institutes of Health (NCT; https://clinicaltrials.gov).
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2 Aim of the Study
In many diseases, a role of neutrophils and CXCR1/2 have been described to be
of pathophysiological relevance. Studies using inhibitory compounds have seen
a reduction of neutrophil influx in many cases and in some cases even improve-
ment of disease characteristics including clinical scores. Basic research shows that
CXCR1/2 are mainly involved in neutrophil adhesion, transmigration and chemo-
taxis. While for chemotaxis there is solid data on the effect of CXCR1/2 inhibition,
its effects on the recruitment cascade have not yet been conclusively clarified.
Therefore, the aim of this project is to elucidate the effects of CXCR1/2 inhibition
on neutrophil recruitment, especially rolling, adhesion and transmigration, using in
vitro and in vivo methods and the new small molecule inhibitors Ladarixin, Repar-
ixin and DF2755A. This will help in better understanding chemokine signaling and
inhibition in neutrophils, and ultimately lead to new therapeutic approaches in the
treatment of CXCR1/2 dependent diseases.
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3 Materials and Methods
3.1 Laboratory Animals
For this study, C57Bl/6 mice were used as wildtype animals (Charles River Labo-
ratories, Sulzfeld, Germany). For multi-photon fluorescence microscopy, Lyz2GFP
mice on C57Bl/6 background were used155. All animals were held at the Core Facil-
ity Animal Models (CAM), Biomedical Centre Munich, Munich, Germany. All animal
experiments were approved by Regierung von Oberbayern, Munich, Germany un-
der AZ 55.2-1-54-2531-122/12.
3.2 Compounds
3.2.1 Buffers and Solutions










10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
0.25% Bovine serum albumin (BSA)
7.4 ± 0.02 adjust pH using NaOH or HCl
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3.2.2 Antibodies
The primary and secondary antibodies used in the experiments are listed below
(Tables 3 and 4).
Table 3: Primary and labeled antibodies.






























Table 4: Secondary antibodies.
Antibody/Reactivity Dye Manufacturer
Donkey anti-rabbit Alexa Fluor 488 Invitrogen/Thermo Fisher
Goat anti-rat Alexa Fluor 546 Invitrogen/Thermo Fisher
3.2.3 Chemokine Receptor Inhibitors
The compounds Ladarixin, Reparixin and DF2755A were generously provided to
us by Dompè S.p.a (L’Aquila, Italy). For the in vitro experiments, we used a tar-
get concentration of 5 µM, and for in vivo 15 or 30 µg/g body weight, which were
the concentrations reported to lie well within the range of inhibition of Ladarixin119,
Reparixin118 and DF2755A137.
3.3 Isolation of Human Neutrophils
Blood was drawn from healthy human donors after obtaining their consent. Heparin
was applied to the syringe at a concentration of 430 international units (IU) Heparin
per 50ml of blood. Around 20-40 ml of blood were drawn. Polymorphprep (Alera
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Technologies, Oslo, Norway) was then added, and the sample was prepared ac-
cording to its application sheet. Briefly, the Polymorphprep solution was added in a
1:1 ratio on top of the blood, then the sample was centrifuged. The top plasma and
peripheral blood mononuclear cell (PBMC) layers were carefully removed, before
removing the polymorphonuclear (PMN) cell layer containing the neutrophils. They
were then washed twice with phosphate-buffered normal saline (PBS).
As a medium for temporarily storing the neutrophils HEPES-buffered Hanks’s salt
solution (HBSS) was used (recipe see above).
The isolated neutrophils were then stained using Tuercks solution, counted in an
improved Neubauer chamber, and the HBSS buffer was added in order to obtain a
concentration of 1x106 cells/ml. Before applying them to the flow chambers, they
were incubated with the compounds or controls.
3.4 Isolation of Murine Neutrophils
C57Bl/6 mice were sacrificed and bone marrow from the hip, femur and tibia bones
was flushed out with PBS. After washing the cells, PMNs were isolated using a
Percoll (Sigma-Aldrich, St. Louis, MO, USA) solution at 1.08 and 1.11 g/ml density.
Cells were counted and resuspended in HBSS at 1x106/ml as described above for
human neutrophils. Subsequently, they were incubated with compounds/controls
for 1h at 37 °C as indicated.
3.5 In Vitro Flow Chambers
µ-Slide VI 0.1 (ibidi GmbH, Martinsried, Germany) plastic microflow chambers were
coated with the specified recombinant proteins at these concentrations: E-selectin
5 µg/ml, ICAM-1 4 µg/ml, CXCL8 10 µg/ml. The proteins were diluted using PBS
with 0.1% BSA. This approach and the concentrations were established before by
the group156. 10 µl of this coating solution was applied to each chamber. After
overnight incubation at 4 °C, Casein in PBS was applied to block unspecific binding
sites. After another 2 hours of incubation at room temperature, the chambers were
flushed with normal saline (0.9% NaCl).
In parallel, 1 ml aliquots of the isolated neutrophil suspension (prepared as de-
scribed before) were incubated for 2 hours at 37 °C with 5% CO2 with the com-
pounds Ladarixin, Reparixin (at the indicated concentrations), and the controls nor-
mal saline, Pertussis Toxin (PTx; 200 ng/ml).
Finally, the flow chambers were placed under an inverse microscope (Zeiss; Ob-
jective Nikon Fluor 20x 0.75) with a heating pad set to 35 °C. The samples were
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drawn up in a syringe and applied using a precision pump (Harvard Apparatus) at a
calculated shear rate of 1 dyne/cm2 while videos were recorded using an MC-1002
CCD camera (Bildsysteme Horn, Aalen, Germany) and VirtualDub software.
3.5.1 Data Analysis
Five to six minutes after the start of the flow the number of rolling and adherent cells
was analyzed. The number of rolling cells was counted as follows: the video was set
to the specified time point. Then, a line was drawn perpendicular to the vessel wall.
When the video was played back for one minute, the number of cells which passed
the line was counted. Similarily, the number of adherent cells was determined:
the video was set to the specified time point, whereafter all the cells were marked.
When the video was played back for one minute, the cells which moved less than
one times their diameter (as determined by the mark) were considered adherent.
3.6 Intravital Microscopy of the Mouse Cremaster Muscle
The cremaster muscle is a thin muscle surrounding the spermatic cord and testis
in mammals on each side. Due to its ease of access and thinness, the cremaster
muscle can be used to study leukocyte interactions with the endothelium and tissue
in vivo. Its use as a model has been first described in 1973157.
The procedure consists of anaesthetizing the mouse using ketamine and xylazine
(recipe see above). The anesthesia is repeated at 1/3 of the above mentioned dose
every hour. The mouse is placed on a heatbed set to 37°C and catheters are placed
in the trachea to stabilize breathing during the surgery and experiment, and carotid
artery to have safe intravascular access in order to apply substances and draw
blood. The scrotum is then cut open, the cremaster muscle is taken out and freed
of connective tissue. Lastly, it is cut open lengthwise and pinned to the stage. For
an example preparation, see Figure 2. During the experiment, it is superfused with
37°C warm superfusion solution (recipe see above).
In this project different approaches using the cremaster muscle were used.
3.6.1 Chemokine-induced Inflammation of the Cremaster Muscle
Inhibitor or saline or pertussis toxin (control) was injected intraperitoneally into
C57Bl/6 mice (Charles River Laboratories, MA, US) at the indicated concentrations,
together with anti-E-selectin antibody at a concentration of 100 µg/mouse where in-
dicated. 1 hour later, 600 ng of recombinant murine KC (ImmunoTools GmbH,
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Figure 2: Example of Cremaster Muscle Preparation. The picture shows the
cremaster muscle of an anesthesized C57Bl/6 mouse after preparation and ready
for microscopy, as seen through the preparation microscope. The blood-filled
vasculature is clearly visible. The testicle which was wrapped in the muscle is
pinned to the stage on the left side (own picture).
Friesoythe, Germany) or recombinant murine CXCL2 (R&D) in 200 µl saline was
injected into the mouse scrotum. After another hour, a carotid artery catheter was
placed, the cremaster muscle was exteriorized and 4-6 vessels per mouse were
recorded as described below. After that, where indicated, the cremaster muscles
were fixed with 4% paraformaldehyde (PFA) on glass slides, colored using Giemsa-
Wright stain and embedded using EUKITT medium (O. Kindler GmbH, Bobingen,
Germany).
3.6.2 Chemokine-induced Neutrophil Arrest in the Cremaster Muscle
Inhibitor or saline (control) or pertussis toxin (PTx, control) was injected i.p. into
C57Bl/6 mice (Charles River Laboratories, MA, US) at a final concentration of 30
µg/g body weight (for PTx 4 µg/mouse). Two hours later, a carotid artery catheter
was placed, the cremaster muscle was exteriorized and the mouse placed on the
stage under the microscope. A suitable vessel was recorded for 1 min, before
600 ng CXCL1 or CXCL8 per mouse was applied through the carotid artery158.
The recording was continued for >5 min thereafter. At the end of the experiments,
systemic blood was taken from the carotid artery and analyzed for leukocyte count
in an IDEXX ProCyte DX hemocytometer (IDEXX Laboratories, ME, US).
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3.6.3 Data Analysis of Adhesion and Rolling
The mouse was then placed on a stage under a BX51WI microscope with water
immersion objective 40x 0.8 NA (both Olympus, Tokyo, Japan) and videos of post-
capillary venules 20-40 µm in diameter were recorded using a CCD camera (CF8/1,
Kappa). Videos were captured using VirtualDub recording software. Vessel di-
ameters, lengths and rolling velocities were analyzed using Fiji software and the
MTrackJ plugin, respectively. The number of rolling and adherent cells was counted
as previously described in section 3.5.1. For the chemokine-induced arrest, cells
were counted before and after applying the chemokine, respectively.
3.6.4 Data Analysis of Transmigration
The Giemsa-Wright stained cremaster muscles were placed under a Leica DM2500
microscope equipped with a DMC2900 CMOS camera. A HCX PL FLUOTAR
100x/1.40 Oil in bright field was used for counting the number of perivascular neu-
trophils, eosinophils, and other WBCs around vessels with a diameter 20-40 µm.
For each mouse, 3-5 field of views were counted.
3.7 Multiphoton Imaging of Neutrophil Transmigration in the
Cremaster Muscle
A dose of 600 ng CXCL2 and fluorescent anti-PECAM-1 Alexa Fluor 546 antibody
was injected intrascrotally into Lyz2GFP (LyE-GFP) mice. Two hours later, the mice
were anesthesized and the cremaster muscle was exteriorized as previously de-
scribed. Images were recorded at the BMC Bioimaging Core Facility with a Leica
SP8 MP upright laser scanning microscope equipped with a 25x1.0 water immer-
sion objective. A pulsed InSight DS+ laser with a set wavelength of 840 nm was
used as a light source. External, non-descanned hybrid photo detectors (HyDs)
were used to acquire images at a resolution of 1024x1024 pixels. Two channels,
corresponding to GFP and Alexa Fluor 546 signals, were captured in a Z stack with
a layer height of 4 µm.
An injury was set in the cremaster using the same laser: the multi-photon laser
was used to scan a 50x50 µm area between vessels 50 times at a high power
setting. Power settings were varied until an injury in the signals could be observed.
Immediately thereafter, video was captured for 30 min.
Videos were analyzed using Fiji software, and the Image Stabilizer plugin. The
Z stacks were combined in a maximum intensity projection, and the GFP intensity
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was measured in a 50x50 µm box around the laser injury. Since the intensities
varied with each experiment, a relative intensity based on the first intensity was
calculated.
3.8 Immunofluorescence Staining of Murine Neutrophils
Murine bone marrow neutrophils were isolated as described above. After treatment
with controls/compounds, they were seeded for 30 min at 37°C, 5% CO2 onto µ-
Slide 8-well glass slides (ibidi GmbH, Martinsried, Germany) coated with PECAM-
1/ICAM-1/chemokine at 2/8/10 µg/ml or 2% BSA (control) respectively. After fixation
with 4% PFA (15min; RT) and permeabilization with 0.1% Triton X-100 and 2% BSA
in PBS (1h; RT), primary antibodies were incubated overnight at 4 °C. Thereafter,
the secondary antibodies (Alexa Fluor 488 and Alexa Fluor 546) were incubated
for 1h at RT. Lastly, labeled anti CD49f antibody was incubated in a single step
overnight at 4 °C. The cells were embedded in PermaFluor.
Confocal microscopy was performed with an inverted Leica SP8X WLL micro-
scope at the BMC Bioimaging Core Facility, equipped with a WLL2 laser and acusto-
optical beam splitter. Images were acquired with a 40x1.2 objective. The following
fluorescence settings were used: Alexa Fluor 488 (excitation 498 nm; emission
508-535 nm), Alexa Fluor 546 (excitation 555 nm; emission 565-620 nm), Alexa
Fluor 647 (excitation 652 nm; emission 662-720 nm). Channels were recorderd se-
quentially to minimize bleed-through. All channels were recorded with hybrid photo
detectors (HyDs). As many cells as possible per FOV were captured using Z stacks
with the "system optimized" setting for Z stack height.
The number of cells showing ring formation in each channel was counted using
Fiji software.
3.9 Statistical Analysis
R and GraphPad software was used for statistical analyses. Comparison of two
experimental groups was done using Student’s t-test t.test(...), independent
or paired - depending on the experimental setting. Comparison of more than
two groups was performed using ANOVA aov(...) and Dunnett’s post-hoc test
glht(..., linfct=mcp(treatment="Dunnett"))). p values > 0.05 were consid-
ered statistically significant.
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4 Results
In the table below the results of the experiments on the effects of Ladarixin, Repar-
ixin and DF2755A on the different phases of neutrophil recruitment are summa-
rized. They are elaborated on in the following subsections.
Table 5: Summary of results
CXCL1 CXCL2 CXCL8 human mouse
in vitro
Rolling - - X •
Adhesion - - X •
in vivo
Rolling - - - •
Acute Adhesion X - X •
Adhesion X X X •
Transmigration ! ! ! •
Interstitial migration - ! - •
This table summarizes the results of experiments done on the different phases of
neutrophil recruitment in this study. Legend: - not investigated, X no significant ef-
fect of inhibitor vs. saline control,!inhibition of this phase of neutrophil recruitment
vs. saline control, • experiments performed in this species. Please see following
section for details.
4.1 In Vitro Rolling and Adhesion
To evaluate the first two stages of neutrophil recruitment - rolling and adhesion -
a microflow chamber assay using isolated human neutrophils was utilized as pre-
viously described in sections 3.3 and 3.5. For the first set of experiments, the
chemokine CXCL8 was immobilized in flow chambers as part of the coating solu-
tion, together with E-selectin and ICAM-1. Here, treatment of cells with Ladarixin
showed 18.3 ± 5.4 rolling cells/FOV, versus 14.18 ± 4.5 for NaCl treatment, and 18
± 2.14 for Reparixin (Figure 3; numbers always mean ± standard error of mean).
For adhesion, the saline control showed 28.9 ± 4.7 cells/FOV, Ladarixin treated
assays 23.3 ± 5.9 and Reparixin treated assays 35.7 ± 6.1 cells/FOV.
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Overall, treatment with Ladarixin or Reparixin did not significantly alter the num-
ber of neither rolling nor adherent cells versus saline control in flow chambers.
Figure 3: Ladarixin and Reparixin do not influence neutrophil rolling and
adhesion in vitro in response to CXCL8. a. Number of rolling leukocytes per
field of view of microflow chambers coated with E-Selectin/ICAM-1/CXCL8. b.
Number of adherent leukocytes per field of view of microflow chambers as
described in a. n ≥ 3, mean ± SEM, n.s. using 2-way ANOVA
In order to investigate the response to CXCL8, a second assay was performed
where the chemokine was not coated onto the chambers, but rather the cells were
pre-treated with it immediately before applying them to the chamber. Also, pertussis
toxin (PTx) was added as a positive control. As can be seen in Figure 4, treatment
of cells with Ladarixin yielded 45.8 ± 9.4 adherent cells/FOV, and Reparixin 53.8 ±
12.1 adherent cells/FOV. Saline treated assays showed 37.8 ± 4.5, and PTx 18.2 ±
1.7 adherent cells/FOV. The difference between NaCl and PTx treatment groups is
statistically significant at p = 0.0042, the differences between NaCl and Ladarixin,
and NaCl and Reparixin treatment groups are not.
Overall, the treatment of neutrophils with PTx led to a significantly reduced num-
ber of adherent cells compared to saline control as expected. Treatment of PMNs
with the compounds Ladarixin or Reparixin did not however significantly influence
the number of adherent cells.
Together, this data shows that Ladarixin and Reparixin do not significantly in-
fluence human PMN adhesion in vitro in response to CXCL8, as evidenced by a
significantly reduced number of adherent neutrophils in a flow chamber assay.
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Figure 4: Ladarixin and Reparixin do not influence neutrophil adhesion in
vitro in response to CXCL8. Number of adherent leukocytes per field of view of
microflow chambers coated with E-Selectin/ICAM-1 after treatment with CXCL8
(10 ng/ml). a. Cells were treated with normal saline (NaCl) or Pertussis toxin (PTx,
200 ng/ml). n ≥ 3, mean ± SEM, p < 0.05 using Students’ t-test. b. Cells were
treated with normal saline (NaCl), Ladarixin (50 µM) or Reparixin (50 µM). n ≥ 3,
mean ± SEM, n.s. using 2-way ANOVA.
4.2 In Vivo Rolling and Adhesion
4.2.1 Acute Induction of Arrest
Based on the fact that CXCR1/2 chemokines are involved in the induction of neu-
trophil arrest, and as shown by the application of CXCL1 and CXCL8 in postcap-
illary venules of the cremaster muscle41,42, we decided to test inhibitors regard-
ing this feature. Experiments were conducted as previously described in section
3.6.2. Briefly, wildtype mice were treated i.p. with either compounds or controls,
and placed under the microscope. While recording the video, they then received
chemokine intravascularly through the cartoid artery catheter.
In the first set of experiments (Figure 5), the application of intravascular CXCL1 in
Ladarixin and saline (control) treated mice both lead to an immediate and significant
increase in the number of adherent cells after the injection as compared to before.
For saline control, the number of adherent cells increased from 276.7 ± 45.1 to
620.4 ± 115.7 per mm2 before and after injection of CXCL1, respectively. For
Ladarixin, adherent cells per mm2 of vessel increased from 369 ± 77.8 pre-injection
to 607.7 ± 79.5 post-injection.
Next we investigated the effects of Ladarixin, Reparixin and DF2755A in response
to CXCL8 in the same model, and also added Pertussis toxin as a second control
(Figure 6). The number of adherent cells per mm2 of vessel wall in NaCl treated
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Figure 5: Ladarixin does not influence acute neutrophil arrest in vivo in
response to CXCL1. Number of adherent leukocytes per mm2 of vessel in the
mouse cremaster muscle, before and after intravascular injection of 600 ng
CXCL1. Mice were pre-treated with a. NaCl or b. Ladarixin (15 µg/g body weight)
i.p. 3 hours before the experiment. n ≥ 3 mice per group. p < 0.05 where indicated
(*) using paired Students’ t-test.
mice increased from 268.5 ± 35.2 pre-injection to 475 ± 31.5 post-injection, in
Ladarixin treated mice from 363.8 ± 33.3 pre-injection to 625.2 ± 32.58 post-
injection, and in DF2755A treated mice from 338.6 ± 31.7 pre-injection to 501.5 ±
45.3 post-injection. In PTx treated mice, the number of adherent cells/mm2 slightly
increased from 291.4 ± 22.4 to 360.3 ± 59.69 post-injection, this increase being
statistically non-significant.
As expected, the change in neutrophil count per mm2 in Pertussis toxin treated
mice did not significantly increase after chemokine injection. In contrast, mice
treated with Ladarixin, Reparixin and DF2755A showed a significant increase af-
ter chemokine injection, similar to saline control.
In summary, here we have shown that Ladarixin, Reparixin and DF2755A do not
influence acute neutrophil arrest in response to intravascularly applied chemokines.
This is evidenced by significant increases in neutrophil adhesion immediately after
chemokine application in mice treated with the compounds, similar to saline treated
mice.
4.2.2 Induction of Tissue Inflammation
A second well-studied effect of chemokines in the cremaster muscle model is the
induction of tissue and vessel inflammation when injected intrascrotally before mi-
croscopy. In short, wildtype mice were treated with compounds or controls i.p.,
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Figure 6: Ladarixin and Reparixin do not influence neutrophil adhesion in
vivo in response to CXCL8. Number of adherent leukocytes per mm2 of vessel in
mouse cremaster, before and after intravascular injection of 600 ng CXCL8. Mice
were pre-treated with NaCl, Ladarixin or Reparixin (both 30 µg/g body weight) or
Pertussis toxin (4 µg/mouse) i.p. 3 hours before the experiment. a. NaCl
pre-treatment, n = 3 mice. b. Ladarixin pre-treatment, n = 3 mice. c. Reparixin
pre-treatment, n = 3 mice. d. Pertussis toxin pre-treatment, n = 5 mice, n.s. p <
0.05 where indicated (*) using paired Students’ t-test.
then chemokine intrascrotally before the number of rolling and adherent cells were
counted (see section 3.6.1 for details).
For rolling, the number of rolling cells in saline treated mice was 23.6 ± 6.8/FOV
versus 18.1 ± 4.7/FOV for Ladarixin treated mice, the difference being statistically
not significant. For adherent cells, saline treated mice showed 637.8 ± 106.2 ad-
herent cells/mm2 and Ladarixin treated mice 642.4 ± 64.7, the the difference being
statistically not significant (Figure 7). Overall there is no significant difference in
neither the number of adherent nor rolling cells in mice treated with Ladarixin i.p.
as compared to mice treated with saline control i.p.
Because of recent findings of differential functions of CXCL1 and CXCL2 regard-
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ing neutrophil recruitment19, we hypothesized that our previous results might be
explained by differential inhibition of chemokines and decided to conduct further
experiments using this model, the two chemokines CXCL1 and CXCL2 and the
inhibitor DF2755A. To investigate this, we performed another set of experiments,
whose results are summarized in Figure 8a (CXCL1 chemokine) and 8b (CXCL2
chemokine). NaCl/CXCL1 treated control mice showed 566.3 ± 85.6 adherent
cells/mm2, and DF2755A/CXCL1 treated mice 453.4 ± 99.8 adherent cells/mm2.
For CXCL2 chemokine, NaCl treated mice showed 502.5 ± 102 and DF2755A
treated mice 458.7 ± 79.7 adherent cells/mm2. The differences between the re-
spective groups are statistically non significant. Overall there is again no significant
difference in the number of adherent cells upon stimulation with either CXCL1 or
CXCL2 and inhibition of CXCR1/2 through DF2755A in comparison with saline con-
trol.
These results show that Ladarixin and DF2755A do not influence neutrophil rolling
and adhesion, as evidenced by non-significant differences in neutrophil adhesion
counts, and additionally neutrophil rolling counts in the case of Ladarixin.
Figure 7: Ladarixin does not influence neutrophil adhesion and rolling in
vivo in response to CXCL1. Data obtained 3 hours after injection of 600ng
CXCL1 intrascrotally, and 4 hours after initial inhibitor/control i.p. injection.
Number of a. rolling cells per field of view, and b. adherent cells per mm2 of vessel
in mouse cremaster. n(NaCl) = 2 mice, n(Ladarixin) = 3 mice, differences are
p>0.05 (n.s.) using Students’ t-test.
4.3 In Vivo Transmigration
As previously discussed, another important role of chemokines in neutrophil re-
cruitment is the induction of transmigration. Therefore, we investigated the effects
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Figure 8: DF2755A does not influence neutrophil adhesion in vivo in
response to CXCL1 or CXCL2. Data obtained 3 hours after injection of 600ng
chemokine intrascrotally, and 4 hours after initial inhibitor/control i.p. injection.
Number of adherent cells per mm2 vessel in mouse cremaster: a. in response to
CXCL1, b. in response to CXCL2. Differences are p>0.05 (n.s.) using unpaired
Students’ t-test. n = 5 mice for all groups, errors bars show SEM.
of DF2755A on CXCL1 and CXCL2, as well as sterile inflammation induced trans-
migration.
The first set of experiments used an in vivo approach described in detail in section
3.7. Briefly, Lyz2GFP neutrophil reporter mice received the compound or saline
control i.p., followed by CXCL2 and labelled Anti-PECAM-1 antibody intrascrotally.
This antibody stains the microvasculature. Then, neutrophil transmigration behavior
was observed using a multiphoton microscope after sterile laser injury using GFP
intensity at injury site as a parameter.
As shown in Figure 10a, the mean relative GFP signal intensity increased from 1,
the relative start point set for each video directly following the laser injury, to a peak
of 4.8 ± 0.8 (28 minutes) for NaCl treated mice and 1.6 ± 0.2 for DF2755A treated
mice. From time point 16 min onwards, the difference between the two groups
are statistically significant. Overall there was a significant difference in the mean
GFP intensity at the injury site, which corresponds to the number of neutrophils,
between saline and DF2755A treated mice from 16 min after laser injury onwards.
Representative images from the two groups can be seen in Figure 10b. Therefore
we had first indications that DF2755A inhibits neutrophil migration to the injury site
(interstitial migration) as well as transmigration.
To confirm the effect on transmigration, we analyzed the Giemsa-stained cremas-
ter muscles of the mice used in the experiments for Figure 8 as described in detail
in section 3.6.4. In short, after the in vivo microscopy experiments the cremas-
ter muscles were Giemsa stained and the number of perivascular leukocytes was
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counted under 100x magnification. NaCl/CXCL1 treated mice had a mean number
of 1822 ± 200 perivascular cells/mm2, while DF/CXCL1 treated mice showed 770 ±
99.4 perivascular cells/mm2 (Figure 9a). For CXCL2 chemokine, NaCl treated mice
showed 1284 ± 153.6 perivascular cells/mm2, and DF2755A treated mice 724.1
± 109.6 perivascular cells/mm2 (Figure 9b). The differences between the respec-
tive groups were statistically significant. The difference between NaCl/CXCL1 and
NaCl/CXCL2 is not statistically significant (p > 0.6, not shown in figure). Overall, the
number of transmigrated cells per mm2 was significantly lower in both CXCL1- and
CXCL2-treated mice compared to saline control. Since neutrophils make up the
majority of leukocytes, we concluded that DF2755A treatment inhibits neutrophil
transmigration in response to CXCL1 and CXCL2. To extend and confirm these
Figure 9: DF2755A and Ladarixin reduce neutrophil transmigration in vivo in
response to CXCL1 or CXCL2. Data from C57Bl6 mice 3 hours after 600 ng
CXCL1/CXCL2 intrascrotally, and 4 hours after initial DF2755A or Ladarixin (both
30µg/g body weight) or NaCl control i.p. injection. Number of perivascular
leukocytes per mm2 tissue in Giemsa-stained mouse cremaster: a. DF2755A
versus saline pre-treatment, CXCL1 chemokine. b. DF2755A versus saline
treatment, CXCL2 treatment. c. Ladarixin versus saline treatment, CXCL1
treatment. n = 5 mice for all groups, errors bars show SEM, p < 0.01 (*) using
unpaired Students’ t-test.
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results, we analyzed cremaster muscles after Ladarixin treatment versus saline
control in the same way. Saline treated control mice showed 506.5 ± 53.5, and
Ladarixin treated mice 161.9 ± 17.8 perivascular cells/mm2. The difference is sta-
tistically significant. Therefore, the number of transmigrated leukocytes is signifi-
cantly smaller in Ladarixin treated mice in comparison to saline control.
Therefore, overall we can conclude that chemokine receptor inhibition using DF-
2755A or Ladarixin inhibits neutrophil transmigration in response to CXCL1, as well
as interstitial migration and transmigration in response to CXCL2 for DF2755A.
Figure 10: DF2755A inhibits Neutrophil Migration towards Sterile
Inflammation Site. a. Neutrophils (green) and microvasculature (red,
anti–PECAM-1) of CXCL2–stimulated mouse cremaster muscle 0 min, 15 min and
30 min after laser injury marked by white box. b. Quantification of neutrophil
transmigration in DF2755A-treated vs. saline-treated mice using relative GFP
intensity at injury site, where time point 0 has the relative intensity 1. p < 0.05
where indicated (*) using Students t-test.
4.4 In Vitro Vesicle Mobilization to the Plasma Membrane
In search for a possible explanation of this inhibition, we turned to a method which
had been established by our group before159. Since neutrophil transmigration de-
pends on translocation of neutrophil elastase (NE), integrins α3β1 (VLA-3) and
α6β1 (VLA-6) to the neutrophil surface (see section 1.1), we hypothesized that
blocking CXCR1/2 blocks this translocation and subsequent transmigration. The
successful translocation can be observed using confocal fluorescence microscopy
as a ring-like structure, corresponding to the protein being enriched at the plasma
membrane. In this assay, isolated murine neutrophils were incubated with com-
pounds/controls and then seeded onto glass slides coated with P-Selectin, ICAM-1
and CXCL1. The cells were then stained against VLA-3, VLA-6 and NE, and eval-
uated for ring formation.
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As can be seen in figure 11b, for the NE channel we found 9.2% ± 3% ring forma-
tion for NaCl treated cells on BSA coating (control) versus 25.4% ± 4.3% for NaCl
treated cells on CXCL1 coating, which is a significant increase. For NE channel
and DF treated cells, 11.4% ± 5.3% ring formation was observed for BSA coating
and 8.4% ± 2.8% for CXCL1 coating, which is not a statistically significant differ-
ence. In the VLA-3 channel (figure 11d), 8.4% ± 2.3% of NaCl treated cells on
BSA versus 32.6% ± 6.9% of NaCl treated cells on CXCL1 showed ring formation,
which is a statistically significant difference. For DF treated cells, 14.5% ± 3% on
BSA versus 16.3% ± 6.3% on CXCL1 coating, which is not a statistically significant
difference. In the VLA-6 channel (figure 11f), 11.8% ± 5% of NaCl treated cells
on BSA versus 23.4% ± 5.9% of NaCl treated cells on CXCL1 showed ring forma-
tion, which is not a statistically significant difference. For DF treated cells, 8.2% ±
3.5% on BSA versus 11% ± 3.6% on CXCL1 coating, which is not a statistically
significant difference. In figure 11a, c and e, representative images for each chan-
nel/treatment/chemokine combination is shown. In summary, DF2755A treatment
of cells did not lead to a statistically significant increase in ring formation in the NE
and VLA-3 channels compared to NaCl treated cells. For VLA-6, either treatment
did not lead to a statistically significant difference.
Therefore our data suggests that DF2755A inhibits the translocation of VLA-3 and
NE to the plasma membrane upon CXCL1 stimulation.
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Figure 11: DF2755A inhibits the translocation of NE and VLA-3 to the plasma
membrane in response to CXCL1. Data from neutrophils isolated from C57Bl6
mice, then treated with 5 µM DF2755A in NaCl or NaCl, respectively.
Representative cells and percentage of cells with ring formation for a, b, c. NE
channel, or d, e, f. VLA-3 channel, or g, h, i. VLA-6 channel, and slides with BSA
or full coating (PECAM-1/ICAM-1/CXCL1 or short CXCL1) as indicated. p < 0.05
where indicated (*) using Students t-test.
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5 Discussion
In this project, we addressed the effects of inhibiting CXCR1/2 through small mole-
cule inhibitors on neutrophil recruitment. Together, the results demonstrate that the
inhibition of these chemokine receptors by the specific CXCR1/2 inhibitors Ladar-
ixin, Reparixin and DF2755A does not have an effect on neutrophil rolling and ad-
hesion, but on transendothelial and interstitial migration (Section 4). The data also
indicates that one possible mechanism for this inhibition of transmigration is the
inhibition of mobilization of NE and VLA-3 to the cell membrane (Fig. 10).
The main in vitro methods for this study were coated microflow chambers and
immunofluorescence staining of murine neutrophils. In vivo methods included ex-
periments using intravital microscopy of the mouse cremaster muscle in brightfield
and using two-photon microscope and the analysis of said cremaster muscles using
Giemsa stains.
Microflow chambers are a widely-used method to study leukocyte interactions
with selected proteins156,159. However, like many in vitro systems, they are some-
what unreliable necessitating a high n number and translating to high statistic spread.
For example in one of our flow chamber experiments, a mean number of 14 cells
could be observed rolling with a standard deviation 5 and a range 3 - 30 in raw data
(Figure 3, NaCl). It is plausible that this is due to different activation states of the
isolated neutrophils, e.g. due to premature activation in vitro. The method could
thus be improved by e.g. temperature controlling the isolated neutrophils (at body
temperature).
Intravital microscopy provides the unique opportunity to observe cells at work in
their physiological milieu, which contributes to the validity of research using these
methods. That being said, one limiting factor of this and most other studies on
the topic are concerning the dynamics of chemokines. In some adhesion experi-
ments, a quick burst of chemokines triggers adhesion. Many diseases discussed
above are of chronic nature and their pathophysiology most probably depends on
continous lower dose chemokine concentrations, which weakens the value of these
experiments. Additionally, our experiments have been performed in line with che-
mokine concentrations previously established in literature, not validated concentra-
tions seen in diseases. For example, a dose of 600 ng CXCL8 intravascularly was
used in the experiments. Using a molecular weight of 14.7 kDa160 and a typical
blood volume of 1.46 ml per mouse, we get a concentration of around 28 nM vs. a
mean measured concentration of 2.5 nM CXCL8 in sputum of COPD patients53. To
this end, the bridge between our preclinical experiments and clinical diseases and
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models has not been completed yet.
Pertussis toxin as a positive inhibitory control has historical roots, since it has
been used since the 1980s for leukocyte adhesion experiments42,127. Its broad
mechanism as a Gai2 protein inhibitor may lead to other, to date not investigated,
effects on signaling. Therefore, the relevance and specificity of experiments using
this compound could be improved using other, more specific inhibitors such as
blocking anti-CXCR1/2 antibodies or Cxcr2−/− mice, both of which have already
been used in research161.
Therefore, experiments with more physiological chemokine dynamics profiles and
more specific controls, would need to be established in order to further validate
these results and bring this research closer "from bench to bedside."
While extensive in vivo studies on neutrophil recruitment were performed and
presented, the experiments on vesicle mobilization experiments still lack more data.
Confirming these results in vivo, e.g. using anti-NE/VLA-3 staining in the mouse
cremaster, would be required before drawing final conclusions.
Also, some combinations of chemokines and inhibitors such as Reparixin or
Ladarixin and CXCL2 in vitro and in vivo could be added to further strengthen the
data and resulting conclusions (see Table 5). Conversely, the multi-photon imaging
experiments could be repeated with CXCL1 and/or CXCL8 as chemokines. How-
ever it is unlikely this will produce different results and change the conclusion: trans-
migration counts in Giemsa stained cremaster were performed with both CXCL2
and CXCL1, and comparing both groups showed non-significance (section 4.3).
Therefore it can be presumed repeating the multi-photon experiments with CXCL1
will not produce different results than CXCL2.
Surprisingly, there was a statistically significant difference in perivascular cells/mm2
between saline controls in DF/CXCL1 and LDX/CXCL1 experiments. NaCl/CXCL1
treated mice in DF experiments had a mean number of perivascular cells of 1822
± 200 (Figure 9a). In LDX experiments, NaCl/CXCL1 treated control mice showed
506.5 ± 53.5 perivascular cells per mm2. The p value using unpaired t test is < 0.01.
The experiments have been performed by different researchers with different levels
of experience in animal experiments in general and cremaster experiment specifi-
cally. Even if the experimental conditions were the same globally, it is plausible that
this difference in animal handling and experiment experience, e.g. handling of mice
during injections, preparation of the cremaster and handling of the cremaster once
exteriorized, explains some of the difference in extravasated cells. A possible mech-
anism is through induction of stress hormones such as cortisol, which suppress the
immune system including neutrophils. On the other hand, part of the difference
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could be explained through inter-observer variability, which is a known bias in many
diagnostic tests depending on observer interpretation of images162,163.
In one other study investigating this issue using similar methods, contradicting
results on the number of adherent cells in vivo were found using Reparixin as an
inhibitor136. However, the experiments performed there were limited with only n=4
mice per group and only Reparixin/CXCL1 as test compounds. Additionally, not
the whole recruitment cascade was analysed. This difference in results highlights
the difficulty of in vivo cremaster experiments, and the subsequent need for a suffi-
ciently high number of experiment sets and animals within them.
As has been described in the literature before, CXCL1, CXCL8 and CXCR1/2
are involved in the induction of arrest/adhesion and transmigration in the neutrophil
recruitment cascade2. On one hand, our results confirm that chemokines play an
important role in neutrophil transmigration. On the other hand, the results concern-
ing rolling and adhesion were unexpected. While indeed, as described before, with
PTx we observed a reduction in neutrophil arrest and adhesion, with the new small
molecule inhibitors this reduction could not be observed. Histopathological studies
on leukocyte transmigration, similar to those performed here, revealed an inhibitory
effect of PTx on this stage as well164.
In the present study, with all used inhibitors, the chemokine can still bind to the
receptor. In the case of PTx this is due to it binding only to the G protein subunits,
not the receptor itself. For DF2755A, Ladarixin and Reparixin this was demon-
strated in radioactive ligand binding assays118,119,137. Therefore, the explanation
for the differential inhibitory behavior of PTx and the new small molecule inhibitors
may lie between binding of the ligand and triggering GPCR signaling. Alternatively
or additionally, the small molecule inhibitors and/or PTx might inhibit other to-date
unknown signaling pathways.
While biased agonism was already discussed for these receptors (section 1.2),
this biased antagonism was only described with CXCR4 so far165. In that study, the
authors showed that using a CXCR4 peptide antagonist, they could inhibit signaling
and chemotaxis through this receptor, but not cause receptor recycling or tolerance.
Similarily, in our study the small molecule inhibitors and/or PTx might only inhibit
part of the signaling through CXCR1/2, respectively.
Concerning other pathways, recently it was reported that CXCR2 associates with
the receptor CCRL2, probably also a G-protein coupled receptor, which is a prereq-
uisite for CXCR2-mediated neutrophil recruitment166. More importantly, the study
specifically showed CCRL2 is required for CXCR2-mediated neutrophil arrest and
β2 integrin activation. Now in our case it might be possible that PTx blocks this
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receptor in addition to CXCR1/2, which could explain the difference in the adhe-
sion/arrest experiments. A key question here would be if CCRL2 is also required
for transmigration.
Regarding chemokines, properties which could explain this difference include
dimerization and elongation/truncation. For CXCL8, a report described different
affinites and intracellular signaling responses to CXCL8 monomer versus dimer167.
Furthermore, it was shown recently that CXCL12 heterodimerizes with a galectin to
modulate leukocyte chemotaxis and recruitment168. Taken together, PTx and/or the
small molecule inhibitors might differentially interfere with chemokine dimerization
which modulates intracellular signaling and ultimately the recruitment phenotype.
Chemokines appear in different elongated and truncated forms which display dif-
ferent biological characteristics36. In that study, there was no significant difference
in neutrophil recruitment of elongated, truncated and intact CXCL8; however a dif-
ference of effect on in vitro chemotaxis was observed. No data has been published
so far on inhibiting the different forms of chemokines, so even though this might not
explain our results, the question still remains what effect different inhibitors have on
the different forms of CXCL8.
From a basic research standpoint, the results of this study maybe open up more
questions than they answer. Especially the missing link between chemokine inhibi-
tion and normal rolling/adhesion is an important open question for future research.
Possible explanations could include biased antagonism at receptor level or other
new pathways like CCRL2.
From a clinical standpoint, small molecule chemokine receptor inhibitors could
provide a very specific inhibition of neutrophils with limited side effects to other parts
of the immune system. Therefore, they have immense potential as immunomodula-
tors. Although there are promising first hints for some diseases like I/R, AD and RA,
it remains to be elucidated in which clinical diseases/conditions and under which
circumstances they benefit the patient. At the same time, testing other neutrophil
chemokine receptor inhibitors for the whole spectrum of neutrophil recruitment like
in this study could ultimately provide useful additional information for their clinical
use. In combining different (neutrophil) inhibitors it may possible to more finely tune
the inhibition of neutrophil recruitment and ultimately tissue damage and disease
activity.
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6 Summary
Neutrophils are key cells of the innate immune system and are the first cells arriving
in acutely inflamed tissue. For this purpose, neutrophils have to extravasate out of
the intravascular compartment into tissue, a prerequisite for their effector function.
While selectins are responsible for tethering and rolling, the chemokine receptors
CXCR1 and 2 in conjunction with leukocyte integrins provide the signaling and acti-
vation events for firm adhesion on the endothelium and subsequent transmigration
into tissue. Neutrophils and CXCR1 and 2 chemokine receptors have been found to
play a role in the pathophysiology of many (auto-)immune diseases and conditions
including ischemia/reperfusion injury, rheumatoid arthritis and Alzheimer’s disease.
Ladarixin, Reparixin and DF2755A are new small molecule inhibitors of CXCR1
and 2. It has been extensively shown that they reduce neutrophil recruitment and
subsequent tissue injury in multiple clinical models including experimental acute
lung injury, ischemia/reperfusion injury and type 1 diabetes mellitus. However, the
exact mechanisms of this therapeutic inhibition have not yet been fully revealed.
Therefore, in this project, we addressed the effects of these drugs on neutrophil
recruitment using in vitro microflow chambers and in vivo mouse cremaster mus-
cle models with brightfield and two-photon laser scanning microscopy. As receptor
ligands we used CXCL1, CXCL2 and CXCL8. In summary, we found that in vitro,
CXCR1 and 2 inhibition by Ladarixin, Reparixin and DF2755A does not significantly
influence human neutrophil rolling and adhesion versus saline control. In vivo, we
found that the inhibitors also do not significantly influence neutrophil rolling and
adhesion, but neutrophil transmigration versus saline controls. This first in-depth
study of small molecule inhibitors and their effect of the recruitment cascade there-
fore helps to explain the molecular mechanism of these compounds and provides
a base for optimizing the treatment of (auto-)immune conditions and diseases us-
ing small molecule chemokine inhibitors. Furthermore, the differential role of che-
mokine inhibition in neutrophils seen here suggests the existence of new, not yet
discovered players in neutrophil recruitment.
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7 Zusammenfassung
Neutrophile Granulozyten spielen eine entscheidende Rolle im angeborenen Im-
munsystem und sind die ersten Zellen, die bei akuter Entzündung ins Gewebe re-
krutiert werden. Dafür migrieren sie aus den Gefäßen ins Gewebe. Selectine sind
zuständig für das Tethering und Rollen, die Chemokinrezeptoren CXCR1 und 2 akti-
vieren zusammen mit Leukozytenintegrinen die benötigten Signalwege für feste Ad-
hesion auf den Endothelzellen und die darauffolgende Transmigration ins Gewebe.
Frühere Untersuchungen zeigen, dass Neutrophile und CXCR1 und 2 Chemokin-
rezeptoren eine Rolle in der Pathophysiologie verschiedener (Auto-)Immunerkrank-
ungen spielen, unter anderem Ischämie/Reperfusionsschäden, rheumatoide Arthri-
tis und Alzheimer-Demenz. Ladarixin, Reparixin und DF2755A sind neue kleinmo-
lekulare Inhibitoren von CXCR1 und 2. Es wurde bereits einschlägig gezeigt, dass
diese Substanzen Neutrophilenrekrutierung und damit einhergehende Gewebszer-
störung in mehreren klinischen Modellen, z.B. experimentelles akutes Lungenver-
sagen, Ischämie/Reperfusionsschäden und Diabetes mellitus Typ 1, verhindern.
Aber die genauen Mechanismen dieser therapeutischen Hemmung sind noch nicht
vollständig aufgeklärt. Daher haben wir in dem vorliegenden Projekt die Effekte die-
ser Substanzen auf Neutrophilenrekrutierung mithilfe in vitro Flusskammern und in
vivo Maus-Cremastermodellen unter Zuhilfenahme von Licht- und Zweiphotonen-
mikroskopie untersucht. Als Rezeptorliganden haben wir CXCL1, CXCL2 und CX-
CL8 verwendet. Zusammengefasst haben wir gefunden, dass CXCR1 und 2 Blo-
ckade mittels der oben gennanten Substanzen - Ladarixin, Reparixin und DF2755A
- das Rollen und die Adhäsion von humanen Neutrophilen in vitro nicht beeinflusst.
Die in vivo Mausexperimente zeigten ebenfalls, dass die Inhibitoren keinen signifi-
kanten Einfluss auf Rollen und Adhäsion von Neutrophilen haben, wohl aber auf die
Transmigration von Neutrophilen. Diese erste ausführliche Untersuchung von Che-
mokinrezeptorinhibitoren und deren Wirkung auf die Neutrophilenrekrutierungskas-
kade hilft daher die molekularen Mechanismen dieser neuen Substanzen besser zu
verstehen und bereitet den Weg für die Optimierung der Therapie verschiedener
(Auto-)Immunerkrankungen mit ihnen. Darüberhinaus deutet die hier gesehene dif-
ferenzelle Chemokinrezeptorblockade bei Neutrophilen auf neue, bisher noch nicht
bekannte Akteure in der Neutrophilenrekrutierung hin.
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Sebastian Sitaru 9 ABBREVATION LIST
9 Abbrevation list
AD Alzheimer’s disease
ALI Acute lung injury
ANC Absolute neutrophil count
ANOVA Analysis of variance
ARDS Acute respiratory distress syndrome
ASH Alcoholic steatohepatitis
BSA Bovine serum albumin
CCLn C-C chemokine ligand n (CCL2 = MCP-1 = monocyte chemoattractant pro-
tein 1, CCL5 = RANTES = regulated on activation, normal T cell expressed
and secreted)
CCRn C-C chemokine receptor n
CCRLn C-C chemokine receptor-like n
COPD Chronic obstructive pulmonary disease
CXCLn C-X-C chemokine receptor ligand n (CXCL8 = IL-8 = interleukin 8; CXCL1
= KC = keratinocyte-derived chemokine)
CXCRn C-X-C chemokine receptor n
DF DF2755A
ECM Extracellular matrix
GPCR G-protein coupled receptor
HPF High power field (100x magnification)
ICAM Intercellular adhesion molecule
I/R Ischemia-reperfusion (injury)
LDX Ladarixin
LFA-1 Lymphocyte function-associated antigen 1 (CD18/CD11a; αLβ2)
CXCR1/2 inhibition in neutrophil recruitment Page 60 of 64
Sebastian Sitaru 9 ABBREVATION LIST
mRNA Messenger ribonucleic acid
NE Neutrophil elastase
NET Neutrophil extracellular traps
RPX Reparixin
PBMC Peripheral blood mononuclear cell
PBS Phosphate-buffered saline
PKD Polycystic kidney disease
PMN Polymorphonuclear leukocyte
PSGL-1 P-selectin glycoprotein ligand 1
PTx Pertussis toxin
RA Rheumatoid arthritis
STIM Stromal interaction molecule
T1D Type 1 diabetes mellitus
TNF-α Tumor necrosis factor α
TRP Transient receptor potential
UC Ulcerative colitis
VLA-3 Very late antigen 3 (α3β1, CD49c/CD29)
VLA-6 Very late antigen 6 (α6β1, CD49f/CD29)
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